Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Steven Nissen, MD, lead investigator for the CLEAR Outcomes trial, spoke with Patient Care® about how gratifying it is to have seen the findings of this landmark study translated into an expanded indication for bempedoic acid, making it the only nonstatin drug approved to reduce CVD risk in both primary and secondary prevention populations.
He describes the experience in this video and acknowledges the challenges still ahead.
Nissen is chief academic officer of the Heart, Vascular, and Thoracic Institute at the Cleveland Clinic, Cleveland, OH, and the primary investigator for the bempedoic acid and bempedoic acid plus ezetimibe clinical trial program, including CLEAR Outcomes. He has devoted decades to clinical research on reduction of risk for cardiovascular disease.
Related Videos
Related Content
